(4) Basal-like or triple-negative breast cancer (TNBC): This subtype is negative for ER, PR, and HER2 (ER−, PR−, HER2−) and is often the most difficult to treat, as it does not respond to hormone therapies or HER2-targeted treatments. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.